News Coverage 08.05.19 By: John Carroll Share on Twitter Share on Facebook Share on LinkedIn Close to a decade after Eli Lilly killed it, Jeffrey Bluestone’s ‘breakthrough’ drug is back and being steered to the FDA Related Announcement, Press Release Parker Institute for Cancer Immunotherapy Names Maria Olson Chief Advancement Officer Announcement, Press Release PICI Invests $1 Million+ in 5 Early Career Researchers Announcement, Patient Story Living Proof: Cancer Vaccine Recipients Bring Their Sto
Announcement, Press Release Parker Institute for Cancer Immunotherapy Names Maria Olson Chief Advancement Officer